These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 21658550)

  • 21. Pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD) decreases the risk for substance abuse: findings from a longitudinal follow-up of youths with and without ADHD.
    Biederman J
    J Clin Psychiatry; 2003; 64 Suppl 11():3-8. PubMed ID: 14529323
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sleep characteristics of children and adolescents with attention deficit-hyperactivity disorder.
    Gruber R
    Child Adolesc Psychiatr Clin N Am; 2009 Oct; 18(4):863-76. PubMed ID: 19836693
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic challenges of attention-deficit hyperactivity disorder with substance use disorders.
    Bukstein OG
    Expert Rev Neurother; 2006 Apr; 6(4):541-9. PubMed ID: 16623653
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Moderators and mediators of symptoms and quality of life outcomes in an open-label study of adults treated for attention-deficit/hyperactivity disorder.
    Weiss MD; Gibbins C; Goodman DW; Hodgkins PS; Landgraf JM; Faraone SV
    J Clin Psychiatry; 2010 Apr; 71(4):381-90. PubMed ID: 20361900
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical recognition and management of adult attention deficit hyperactivity disorder.
    Craig C
    Nurse Pract; 1996 Nov; 21(11):101-6, 108. PubMed ID: 8933539
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnosing attention-deficit/hyperactivity disorder in patients with substance use disorders.
    Levin FR
    J Clin Psychiatry; 2007; 68 Suppl 11():9-14. PubMed ID: 18307376
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Neurobiology of attention deficit/hyperactivity disorder].
    Purper-Ouakil D; Lepagnol-Bestel AM; Grosbellet E; Gorwood P; Simonneau M
    Med Sci (Paris); 2010 May; 26(5):487-96. PubMed ID: 20510147
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Attention-deficit/hyperactivity disorder in elite athletes: a narrative review.
    Han DH; McDuff D; Thompson D; Hitchcock ME; Reardon CL; Hainline B
    Br J Sports Med; 2019 Jun; 53(12):741-745. PubMed ID: 31097459
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacotherapy of attention deficit hyperactivity disorder.
    Spencer T; Biederman J; Wilens T
    Child Adolesc Psychiatr Clin N Am; 2000 Jan; 9(1):77-97. PubMed ID: 10674191
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stimulant effects in attention deficit hyperactivity disorder: theoretical and empirical issues.
    Denney CB
    J Clin Child Psychol; 2001 Mar; 30(1):98-109. PubMed ID: 11294083
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Managing attention-deficit/hyperactivity disorder in primary care: a systematic analysis of roles and challenges.
    Power TJ; Mautone JA; Manz PH; Frye L; Blum NJ
    Pediatrics; 2008 Jan; 121(1):e65-72. PubMed ID: 18166546
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Attention-deficit hyperactivity disorder (ADHD) and tuberous sclerosis complex.
    D'Agati E; Moavero R; Cerminara C; Curatolo P
    J Child Neurol; 2009 Oct; 24(10):1282-7. PubMed ID: 19805824
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Attention deficit/hyperactivity disorder and psychopharmacologic treatments in the athlete.
    Conant-Norville DO; Tofler IR
    Clin Sports Med; 2005 Oct; 24(4):829-43, viii. PubMed ID: 16169448
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder.
    Fone KC; Nutt DJ
    Curr Opin Pharmacol; 2005 Feb; 5(1):87-93. PubMed ID: 15661631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Attention Deficit Hyperactivity Disorder in Athletes.
    Ciocca M
    Clin Sports Med; 2019 Oct; 38(4):545-554. PubMed ID: 31472765
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Managing attention-deficit/hyperactivity disorder in the presence of substance use disorder.
    Upadhyaya HP
    J Clin Psychiatry; 2007; 68 Suppl 11():23-30. PubMed ID: 18307378
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Executive dysfunction in attention-deficit/hyperactivity disorder: cognitive and neuroimaging findings.
    Roth RM; Saykin AJ
    Psychiatr Clin North Am; 2004 Mar; 27(1):83-96, ix. PubMed ID: 15062632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bipolar disorders and quality of life: the impact of attention deficit/hyperactivity disorder and substance abuse in euthymic patients.
    Sentissi O; Navarro JC; De Oliveira H; Gourion D; Bourdel MC; Baylé FJ; Olié JP; Poirier MF
    Psychiatry Res; 2008 Oct; 161(1):36-42. PubMed ID: 18786727
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Attention-deficit/hyperactivity disorder: a life-span perspective.
    Biederman J
    J Clin Psychiatry; 1998; 59 Suppl 7():4-16. PubMed ID: 9680048
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Attention-deficit/hyperactivity disorder: diagnosis, lifespan, comorbidities, and neurobiology.
    Spencer TJ; Biederman J; Mick E
    J Pediatr Psychol; 2007 Jul; 32(6):631-42. PubMed ID: 17556405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.